LY-517717

CAS No. 313489-71-3

LY-517717( LY 517717 | LY517717 )

Catalog No. M14007 CAS No. 313489-71-3

A potent, selective, and orally bioavailable factor Xa (FXa) inhibitor for prevention and treatment of thromboembolic diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LY-517717
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective, and orally bioavailable factor Xa (FXa) inhibitor for prevention and treatment of thromboembolic diseases.
  • Description
    A potent, selective, and orally bioavailable factor Xa (FXa) inhibitor for prevention and treatment of thromboembolic diseases.Thrombosis Phase 2 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    LY 517717 | LY517717
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Factor Xa
  • Recptor
    Factor Xa
  • Research Area
    Cardiovascular Disease
  • Indication
    Thrombosis

Chemical Information

  • CAS Number
    313489-71-3
  • Formula Weight
    459.59
  • Molecular Formula
    C27H33N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=CC2=C(C=C1)C=CN2)N[C@H](C3=CC=CC=C3)C(N4CCN(C5CCN(C)CC5)CC4)=O
  • Chemical Name
    (R)-N-(2-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-2-oxo-1-phenylethyl)-1H-indole-6-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kubitza D, et al. Expert Opin Investig Drugs. 2006 Aug;15(8):843-55. 2. Ahrens I, et al. Discov Med. 2012 Jun;13(73):445-50.
molnova catalog
related products
  • Rivaroxaban

    A highly potent and selective, direct FXa inhibitor with IC50 of 0.7 nM.

  • Eribaxaban

    A potent, selective and orally efficacious factor Xa (FXa) inhibitor with IC50 of 0.32 nM.

  • 4-Chlorophenylurea

    4-Chlorophenylurea is a novel orally bioavailable inhibitor of factor Xa.